Floatz logo

TEGAFUR

T3 or T4 (Only Anal Extension) Rectal Cancer

Institut Cancerologie de l'OuestSmall moleculePhase 3Dormant
B
59/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
44/ 100
Competitive Position
95/ 100

Competitive context

70 Active assets in the T3 or T4 (Only Anal Extension) Rectal Cancer cohort.

Asset / SponsorPhaseRating
Irinotecan
Sun Yat-sen University
Phase 4BBB
FLUOROURACILUM
Seoul National University Hospital
Phase 3BBB
Eloxatin
Sun Yat-sen University
Phase 3BBB
Irinotecan
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 3BB
Capecitabine
Tao Zhang
Phase 3BB

View all 50 →

Same molecule, other indications

TEGAFUR is also rated in:

Adjuvant ChemotherapyDormant
B
Indicative ·
59 / 100
View asset →
cervical intraepithelial neoplasia grade 2/3Dormant
B
Indicative ·
59 / 100
View asset →
breast cancerDormant
B
Indicative ·
58 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →